18F-FDG—PET/CT in Canine Mammary Gland Tumors

Diana Sánchez, Laura Romero, Sergio López, Margarita Campuzano, Rocio Ortega, Alfonso Morales, Marina Guadarrama, Gabriela Cesarman-Maus, Osvaldo García-Pérez, Marcela Lizano

Research output: Contribution to journalArticle

Abstract

Medical imaging techniques play a central role in clinical oncology, helping to obtain important information about the extent of disease, and plan treatment. Advanced imaging modalities such as Positron Emission Tomography–Computed Tomography (PET/CT), may help in the whole-body staging in a single procedure, although the lesions should be carefully interpreted. PET/CT is becoming commonly used in canine cancer patients, but there is still limited information available on specific tumors such as mammary cancer. We evaluated the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/CT to detect malignant lesions in eight female dogs with naturally occurring mammary tumors. A whole-body scan was performed prior to surgery, and mammary and non-mammary lesions detected either on PET/CT or during pre-surgical physical exam were resected when possible and submitted for histopathological examination. Multiple mammary lesions involving different mammary glands were detected in 5/8 dogs, for a total of 23 lesions; there were 11 non-mammary-located lesions in 6/8 dogs, three of these were lung or lymph node metastasis. A total of 34 lesions were analyzed: 22 malignant (19 mammary tumors and three metastatic lesions), and 12 benign (four mammary lesions and eight of non-mammary tissues). Glucose uptake by maximum standardized uptake value (SUVmax) was analyzed and correlated with tumor size, and benign vs. malignant pathology. We found that the minimum tumor size needed to distinguish malignant lesions according to the SUVmax was 1.5 cm; benign and malignant lesions <1.5 cm did not differ in glucose uptake (mean SUVmax = 1.1). In addition, a SUVmax value >2 was 100% sensitive for malignancy. Combining these data, lesions >1.5 cm with a SUVmax >2 had a positive predictive value of 100%. Finally, we did not find an association between SUVmax and histologic subtype or grade, which may be present in a larger sample. Thus, 18F-FDG PET/CT is useful for distinguishing malignant from benign lesion but further imaging of dogs with diverse tumors, should establish characteristic SUV value cutoffs for detecting primary and metastatic disease, and distinguishing them from benign lesions.

Original languageEnglish (US)
Article number280
JournalFrontiers in Veterinary Science
Volume6
DOIs
StatePublished - Aug 27 2019

Fingerprint

mammary neoplasms (animal)
Human Mammary Glands
lesions (animal)
Canidae
Positron-Emission Tomography
Breast Neoplasms
dogs
Fluorodeoxyglucose F18
Dogs
positron-emission tomography
Neoplasms
Breast
neoplasms
breasts
Whole Body Imaging
Medical Oncology
Diagnostic Imaging
image analysis
Lymph Nodes
Pathology

Keywords

  • F-FDG
  • PET/CT
  • cancer diagnosis
  • canine mammary gland tumors
  • molecular imaging

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Sánchez, D., Romero, L., López, S., Campuzano, M., Ortega, R., Morales, A., ... Lizano, M. (2019). 18F-FDG—PET/CT in Canine Mammary Gland Tumors. Frontiers in Veterinary Science, 6, [280]. https://doi.org/10.3389/fvets.2019.00280

18F-FDG—PET/CT in Canine Mammary Gland Tumors. / Sánchez, Diana; Romero, Laura; López, Sergio; Campuzano, Margarita; Ortega, Rocio; Morales, Alfonso; Guadarrama, Marina; Cesarman-Maus, Gabriela; García-Pérez, Osvaldo; Lizano, Marcela.

In: Frontiers in Veterinary Science, Vol. 6, 280, 27.08.2019.

Research output: Contribution to journalArticle

Sánchez, D, Romero, L, López, S, Campuzano, M, Ortega, R, Morales, A, Guadarrama, M, Cesarman-Maus, G, García-Pérez, O & Lizano, M 2019, '18F-FDG—PET/CT in Canine Mammary Gland Tumors', Frontiers in Veterinary Science, vol. 6, 280. https://doi.org/10.3389/fvets.2019.00280
Sánchez D, Romero L, López S, Campuzano M, Ortega R, Morales A et al. 18F-FDG—PET/CT in Canine Mammary Gland Tumors. Frontiers in Veterinary Science. 2019 Aug 27;6. 280. https://doi.org/10.3389/fvets.2019.00280
Sánchez, Diana ; Romero, Laura ; López, Sergio ; Campuzano, Margarita ; Ortega, Rocio ; Morales, Alfonso ; Guadarrama, Marina ; Cesarman-Maus, Gabriela ; García-Pérez, Osvaldo ; Lizano, Marcela. / 18F-FDG—PET/CT in Canine Mammary Gland Tumors. In: Frontiers in Veterinary Science. 2019 ; Vol. 6.
@article{22a3483128314d9f8a838917dca07b93,
title = "18F-FDG—PET/CT in Canine Mammary Gland Tumors",
abstract = "Medical imaging techniques play a central role in clinical oncology, helping to obtain important information about the extent of disease, and plan treatment. Advanced imaging modalities such as Positron Emission Tomography–Computed Tomography (PET/CT), may help in the whole-body staging in a single procedure, although the lesions should be carefully interpreted. PET/CT is becoming commonly used in canine cancer patients, but there is still limited information available on specific tumors such as mammary cancer. We evaluated the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/CT to detect malignant lesions in eight female dogs with naturally occurring mammary tumors. A whole-body scan was performed prior to surgery, and mammary and non-mammary lesions detected either on PET/CT or during pre-surgical physical exam were resected when possible and submitted for histopathological examination. Multiple mammary lesions involving different mammary glands were detected in 5/8 dogs, for a total of 23 lesions; there were 11 non-mammary-located lesions in 6/8 dogs, three of these were lung or lymph node metastasis. A total of 34 lesions were analyzed: 22 malignant (19 mammary tumors and three metastatic lesions), and 12 benign (four mammary lesions and eight of non-mammary tissues). Glucose uptake by maximum standardized uptake value (SUVmax) was analyzed and correlated with tumor size, and benign vs. malignant pathology. We found that the minimum tumor size needed to distinguish malignant lesions according to the SUVmax was 1.5 cm; benign and malignant lesions <1.5 cm did not differ in glucose uptake (mean SUVmax = 1.1). In addition, a SUVmax value >2 was 100{\%} sensitive for malignancy. Combining these data, lesions >1.5 cm with a SUVmax >2 had a positive predictive value of 100{\%}. Finally, we did not find an association between SUVmax and histologic subtype or grade, which may be present in a larger sample. Thus, 18F-FDG PET/CT is useful for distinguishing malignant from benign lesion but further imaging of dogs with diverse tumors, should establish characteristic SUV value cutoffs for detecting primary and metastatic disease, and distinguishing them from benign lesions.",
keywords = "F-FDG, PET/CT, cancer diagnosis, canine mammary gland tumors, molecular imaging",
author = "Diana S{\'a}nchez and Laura Romero and Sergio L{\'o}pez and Margarita Campuzano and Rocio Ortega and Alfonso Morales and Marina Guadarrama and Gabriela Cesarman-Maus and Osvaldo Garc{\'i}a-P{\'e}rez and Marcela Lizano",
year = "2019",
month = "8",
day = "27",
doi = "10.3389/fvets.2019.00280",
language = "English (US)",
volume = "6",
journal = "Frontiers in Veterinary Science",
issn = "2297-1769",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - 18F-FDG—PET/CT in Canine Mammary Gland Tumors

AU - Sánchez, Diana

AU - Romero, Laura

AU - López, Sergio

AU - Campuzano, Margarita

AU - Ortega, Rocio

AU - Morales, Alfonso

AU - Guadarrama, Marina

AU - Cesarman-Maus, Gabriela

AU - García-Pérez, Osvaldo

AU - Lizano, Marcela

PY - 2019/8/27

Y1 - 2019/8/27

N2 - Medical imaging techniques play a central role in clinical oncology, helping to obtain important information about the extent of disease, and plan treatment. Advanced imaging modalities such as Positron Emission Tomography–Computed Tomography (PET/CT), may help in the whole-body staging in a single procedure, although the lesions should be carefully interpreted. PET/CT is becoming commonly used in canine cancer patients, but there is still limited information available on specific tumors such as mammary cancer. We evaluated the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/CT to detect malignant lesions in eight female dogs with naturally occurring mammary tumors. A whole-body scan was performed prior to surgery, and mammary and non-mammary lesions detected either on PET/CT or during pre-surgical physical exam were resected when possible and submitted for histopathological examination. Multiple mammary lesions involving different mammary glands were detected in 5/8 dogs, for a total of 23 lesions; there were 11 non-mammary-located lesions in 6/8 dogs, three of these were lung or lymph node metastasis. A total of 34 lesions were analyzed: 22 malignant (19 mammary tumors and three metastatic lesions), and 12 benign (four mammary lesions and eight of non-mammary tissues). Glucose uptake by maximum standardized uptake value (SUVmax) was analyzed and correlated with tumor size, and benign vs. malignant pathology. We found that the minimum tumor size needed to distinguish malignant lesions according to the SUVmax was 1.5 cm; benign and malignant lesions <1.5 cm did not differ in glucose uptake (mean SUVmax = 1.1). In addition, a SUVmax value >2 was 100% sensitive for malignancy. Combining these data, lesions >1.5 cm with a SUVmax >2 had a positive predictive value of 100%. Finally, we did not find an association between SUVmax and histologic subtype or grade, which may be present in a larger sample. Thus, 18F-FDG PET/CT is useful for distinguishing malignant from benign lesion but further imaging of dogs with diverse tumors, should establish characteristic SUV value cutoffs for detecting primary and metastatic disease, and distinguishing them from benign lesions.

AB - Medical imaging techniques play a central role in clinical oncology, helping to obtain important information about the extent of disease, and plan treatment. Advanced imaging modalities such as Positron Emission Tomography–Computed Tomography (PET/CT), may help in the whole-body staging in a single procedure, although the lesions should be carefully interpreted. PET/CT is becoming commonly used in canine cancer patients, but there is still limited information available on specific tumors such as mammary cancer. We evaluated the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/CT to detect malignant lesions in eight female dogs with naturally occurring mammary tumors. A whole-body scan was performed prior to surgery, and mammary and non-mammary lesions detected either on PET/CT or during pre-surgical physical exam were resected when possible and submitted for histopathological examination. Multiple mammary lesions involving different mammary glands were detected in 5/8 dogs, for a total of 23 lesions; there were 11 non-mammary-located lesions in 6/8 dogs, three of these were lung or lymph node metastasis. A total of 34 lesions were analyzed: 22 malignant (19 mammary tumors and three metastatic lesions), and 12 benign (four mammary lesions and eight of non-mammary tissues). Glucose uptake by maximum standardized uptake value (SUVmax) was analyzed and correlated with tumor size, and benign vs. malignant pathology. We found that the minimum tumor size needed to distinguish malignant lesions according to the SUVmax was 1.5 cm; benign and malignant lesions <1.5 cm did not differ in glucose uptake (mean SUVmax = 1.1). In addition, a SUVmax value >2 was 100% sensitive for malignancy. Combining these data, lesions >1.5 cm with a SUVmax >2 had a positive predictive value of 100%. Finally, we did not find an association between SUVmax and histologic subtype or grade, which may be present in a larger sample. Thus, 18F-FDG PET/CT is useful for distinguishing malignant from benign lesion but further imaging of dogs with diverse tumors, should establish characteristic SUV value cutoffs for detecting primary and metastatic disease, and distinguishing them from benign lesions.

KW - F-FDG

KW - PET/CT

KW - cancer diagnosis

KW - canine mammary gland tumors

KW - molecular imaging

UR - http://www.scopus.com/inward/record.url?scp=85072734752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072734752&partnerID=8YFLogxK

U2 - 10.3389/fvets.2019.00280

DO - 10.3389/fvets.2019.00280

M3 - Article

AN - SCOPUS:85072734752

VL - 6

JO - Frontiers in Veterinary Science

JF - Frontiers in Veterinary Science

SN - 2297-1769

M1 - 280

ER -